Immunovaccine Inc. Signs Collaboration Agreement with National Cancer Institute
|
| Posted
:
Tue, 10 Nov 2009 13:46:03 GMT |
| Author
:
Immunovaccine Inc. |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
HALIFAX, NOVA SCOTIA -- 11/10/09 --
Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, USA. The research collaboration involves formulating NCI's cancer vaccine antigens in DepoVax(TM), Immunovaccine's vaccine enhancement system.
"NCI is a world leader in the study of cancer biology and cancer therapy and we look forward to seeing how our enhanced DepoVax(TM) delivery system improves immune responses to treat cancer," said Dr. Marc Mansour, vice president of R&D at Immunovaccine.
The research team at Immunovaccine will be collaborating with NCI investigator Dr. Jeffrey Schlom, head of the Immunotherapeutics group and chief of the Laboratory of Tumor Immunology & Biology. Dr. Schlom has significant ongoing research in the study of cancer vaccines and is well published in the design and characterization of recombinant vaccines for cancer therapy.
DepoVax(TM) is a vaccine enhancement and delivery platform which has demonstrated ability to enhance the immunogenicity of antigens by creating a strong "depot" at the site of immunization. Immunovaccine has previously shown eradication of tumors in three animal models with results published in peer reviewed journals. Immunovaccine has proven its scale-up capabilities at a contract manufacturing site with the ability to manufacture DepoVax(TM) - based vaccines for human clinical trials.
Immunovaccine Inc. (TSX VENTURE: IMV) is focused on the commercialization of its novel vaccine technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Immunovaccine Inc.
Dr. Marc Mansour
Vice President R&D
(902) 492-1819
info@imvaccine.com
Immunovaccine Inc.
Jennifer Ayotte
Director Communications
(902) 492-1819
jayotte@imvaccine.com
www.imvaccine.com
|

Copyright © 2008
Market Wire. All
rights reserved.
|
|
|
|
|
Related
News
Woolly Pockets, the vertical garden system, hits the UK in time for Christmas
Woolly Wally Pockets, the great vertical garden system, are now available in the UK through Garden Beet (a href= http://www.gardenbeet.com/ onclick= linkClick( this.href ); target= _blank http://www.gardenbeet.com//a) offering an alternative environmentally friendly Christmas gift idea...
MINDlink Foundation Launches to Connect the Cerebellum to Cures
Pioneering Neurologist Closer to Understanding Brain Wiring and Diseases
WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School and neurologist at the Massachusetts General Hospital in Boston, on Thursday, Novemb...
New Tri Tax President and CEO Frank Montano Brings Years of Corporate Leadership to Booming Company
SAN PEDRO, Calif., Nov. 20 /PRNewswire/ -- In an effort to help the company manage its phenomenal growth, Tri Tax is pleased to welcome seasoned business executive and franchising expert Frank Montano in the position of President and CEO. Current President and CEO Carlos Marquez, fo...
Zimbabwean Rights Defender and Movement to Receive RFK Award at White House Ceremony
WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Magodonga Mahlangu and her organization, Women of Zimbabwe Arise (WOZA), will receive the 2009 Robert F. Kennedy Human Rights Award at an evening ceremony to be held at the White House November 23rd, featuring remarks by President Barack Ob...
Jury Assesses a $10.2 Million Verdict for Retired Washington Paper Mill Worker Suffering from Mesothelioma
A former Washington paper mill worker, diagnosed with mesothelioma after years of asbestos exposure, was assessed a $10.2 million verdict. In trial, it was demonstrated that the defendants defective asbestos containing products were a contributing cause to his asbestos cancer./I/P
P(PRW...
Sarraf Gentile LLP Announces Class Action Against SunPower Corporation NEW YORK, NY -- 11/20/09 --
Sarraf Gentile LLP announces that a class
action lawsuit was filed against SunPower Corporation (NASDAQ: SPWRA) and
certain of its officers and directors on behalf of those who purchased
SunPower's common stock between A..
CKE Restaurants, Inc. to Participate in Wedbush Conference CARPINTERIA, Calif. -
CKE Restaurants, Inc. (NYSE: CKR) will be participating in the Wedbush 10th
Annual California Dreamin’ Conference on December 9, 2009. Details are
as follows:
|
|
|
|
|
|
|
|
|